ClinicalTrials.gg
CompletedNCT00577031Updated Aug 18, 2015Results posted

OBELIX Study: A Study of Avastin (Bevacizumab) in Combination With XELOX in Patients With Metastatic Cancer of the Colon or Rectum.

A Phase 4 interventional study of bevacizumab [Avastin] and Oxaliplatin in Colorectal Cancer, sponsored by Hoffmann-La Roche. Completed at 38 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-08-18.

Sponsored by Hoffmann-La Roche · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
205
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 230 studies testing bevacizumab in Colorectal Neoplasms — 49 open to participants now, 61 under way, 11 of them phase 3. Bevacizumab · Colorectal Neoplasms.

Enrollment
52nd of 224
205 · median 63
Started
2008
with 9 others
Phase 4
8 of 230
1 open now
Registered
58th of 230
by date
Lead sponsor
22 of 230
Hoffmann-La Roche

Among the 230 studies testing bevacizumab in Colorectal Neoplasms, this one is the 52nd largest by enrollment of the 224 interventional ones that give a count, is one of 10 that started in 2008, is one of 8 in phase 4, and was the 58th registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

49 of the 230 studies testing bevacizumab in Colorectal Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

44 more — sign in →

By country, each count listing its studies:

All 49 open studies →

About bevacizumab

Bevacizumab: first FDA approval 2004 (AVASTIN), first EMA approval 2005. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 230 studies testing bevacizumab in Colorectal Neoplasms, or all of them as a file.
02

Study summary

This single arm study will evaluate the efficacy and safety of a first-line regimen of Avastin and XELOX (oxaliplatin + Xeloda) in patients with metastatic cancer of the colon or rectum. Patients will receive 21-day cycles of treatment, comprising Avastin 7.5mg/kg iv on day 1, oxaliplatin 130mg/m2 iv on day 1, and Xeloda 1000mg/m2 po twice daily on days 1-14, for a maximum of 6 months. Patients with stable disease or complete or partial response may continue on Avastin therapy. The anticipated time on study treatment is until disease progression, and the target sample size is 100-500 individuals.

03

Conditions studied

  • Colorectal Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • adult patients, >=18 years of age;
  • locally advanced or colorectal cancer;
  • no previous treatment with chemotherapy for metastatic disease;
  • at least one .

Exclusion criteria

Exclusion Criteria:

  • radiotherapy to any site within 4 weeks before study;
  • untreated or primary brain tumors;
  • cardiovascular disease;
  • chronic daily treatment with high dose aspirin (>325 mg/day);
  • other co-existing or malignancies diagnosed within last 5 years.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
205 participants (actual)

Study arms

  • Experimental
    1

    Drug: bevacizumab [Avastin] · Drug: Oxaliplatin · Drug: Xeloda

Interventions

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS): Percentage of Participants With Progressive Disease or Death

    PFS was defined as the time period in months from the start of study treatment to the first observation of disease progression or death from any cause, whichever occurred first. Data for participants with no tumor assessments after baseline but who were still alive at the time of the clinical cutoff were censored at Day 1. Participants who underwent surgery after experiencing a sufficient shrinkage of the tumor, had any relapse, new occurrence of colorectal cancer, or who died were all considered as having had an event. Participants who underwent surgery without any such event were censored at the date of the last tumor assessment that documented neither a relapse nor a new colorectal cancer had occurred. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20 percent (%) increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.

    Time frame: Baseline and Day 1 of every cycle until disease progression or death up to 5 years

  2. PFS: Time to Event

    PFS was defined as the time period in months from the start of study treatment to the first observation of disease progression or death from any cause, whichever occurred first. Data for participants with no tumor assessments after baseline but who were still alive at the time of the clinical cutoff were censored at Day 1. Participants who underwent surgery after experiencing a sufficient shrinkage of the tumor, had any relapse, new occurrence of colorectal cancer, or who died were all considered as having had an event. Participants who underwent surgery without any such event were censored at the date of the last tumor assessment that documented that neither a relapse nor a new colorectal cancer had occurred. Median PFS was estimated using the Kaplan-Meier method.

    Time frame: Baseline and Day 1 of every cycle until disease progression or death up to 5 years

Secondary outcomes

  1. Percentage of Participants With a Best Overall Response of Complete Response (CR) or Partial Response (PR) Among Participants in the ITT Population Who Had at Least 1 Post-Baseline Assessment

    The percentage of participants with a best overall response of CR or PR according to RECIST. CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must have decreased to normal (short axis less than \[\<\]10 millimeters \[mm\]). No new lesions. PR was defined as a greater than or equal to (≥) 30% decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions.

    Time frame: Baseline, every 9 weeks (every 3 cycles) until end of treatment, disease progression, or withdrawal up to 5 years

  2. Percentage of Participants With a CR or PR Among Participants in the ITT Population

    CR and PR were defined using RECIST v1.0. CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must have decreased to normal (short axis \<10 mm). No new lesions. PR was defined as a ≥30% decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions.

    Time frame: Baseline, every 9 weeks (every 3 cycles) until end of treatment, disease progression, or withdrawal up to 5 years

  3. Time to CR or PR Overall Response - Time to Event

    Time to overall response (CR or PR) was calculated as the time between the date of start of treatment until first documented response (CR or PR defined per RECIST v1.0). Participants who did not achieve CR or PR were censored at the date of progression, death, or at last adequate tumor assessment date. Median time to CR or PR overall response was estimated using the Kaplan-Meier method.

    Time frame: Baseline, every 9 weeks (every 3 cycles) until end of treatment, disease progression, or withdrawal up to 5 years

  4. Percentage of Participants With a Best Overall Response of CR or PR During First Line Treatment

    CR and PR were defined using RECIST v1.0 criteria. CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must have decreased to normal (short axis \<10 mm). No new lesions. PR was defined as a ≥30% decrease under baseline of the sum of diameters of all target lesions. Short axis was used in sum for target nodes, while longest diameter was used in sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions.

    Time frame: Baseline, every 3 weeks (every cycle) to disease progression or death up to 5 years

  5. Duration of Overall Response Among Participants Whose Best Response Was CR or PR During First Line Treatment - Time to Event

    For participants with a best overall response of CR or PR, the duration of overall response was measured from the time that the criteria for CR or PR (whichever occurred first) was met until the first date that progressive disease was objectively documented or until the date of death due to underlying cancer, whichever occurred first. Data for participants who did not have an event or who were alive without an objectively documented progressive disease were censored at the date of last adequate tumor assessment. Median duration of overall response was estimated using the Kaplan-Meier method.

    Time frame: Baseline, every 3 weeks (every cycle) to disease progression or death up to 5 years

  6. Percentage of Participants With a Stable Response During First Line Treatment

    Stable response defined as participants with a best overall response of CR, PR, or stable disease (SD), defined using RECIST v1.0 criteria. CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must have decreased to normal (short axis \<10 mm). No new lesions. PR was defined as a ≥30% decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions. SD defined as neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease, taking as reference the smallest sum longest diameter since the treatment started.

    Time frame: Baseline, every 3 weeks (every cycle) to disease progression or death up to 5 years

  7. Duration of Stable Response

    For participants with a best overall response of CR, PR, or SD during first line treatment, the duration of stable response was measured from the time that the criteria for CR, PR, or SD (whichever occurred first) was met until the first date that progressive disease was objectively documented or until the date of death due to underlying cancer, whichever occurred first. Data for participants who did not have an event or who were alive without an objectively documented progressive disease were censored at the date of last adequate tumor assessment. Median duration of stable response was estimated using the Kaplan-Meier method.

    Time frame: Baseline, every 3 weeks (every cycle) to disease progression or death up to 5 years

  8. Percentage of Participants With Treatment Failure

    Treatment-failure was defined as discontinuation of treatment for any reason, including the following qualifying events: death due to any cause, adverse event, insufficient therapeutic response (progression of disease), failure to return (lost to follow-up), refusing treatment (participant non-compliance), being unwilling to cooperate and withdrawing consent (participant withdrew consent).

    Time frame: Baseline, every 3 weeks (every cycle) to disease progression or death up to 5 years

  9. Time to Treatment Failure

    Time to treatment-failure was defined as the time from the first day of treatment to discontinuation of treatment for any reason, including: death due to any cause, adverse event, insufficient therapeutic response (progression of disease), failure to return (lost to follow-up), refusing treatment (participant non-compliance), being unwilling to cooperate and withdrawing consent (participant withdrew consent). For participants who did not experience a qualifying event, their data were censored at the earlier of either the date of last tumour assessment or the date of the last intake of study medication. Median time to treatment-failure was estimated using the Kaplan-Meier method.

    Time frame: Baseline, every 3 weeks (every cycle) to disease progression or death up to 5 years

  10. Overall Survival: Percentage of Participants That Died Due to Any Cause

    Overall survival was defined as the time from the date of the first day of treatment until the date of death from any cause. If a participant was not known to have died, survival was censored at the last date the participant was known to be alive.

    Time frame: Baseline, Day 1 of every cycle to end-of-treatment, every 3 months during longer-term follow-up, or to death due to any cause up to 5 years

  11. Overall Survival: Time to Event

    Overall survival was defined as the time from the date of the first day of treatment until the date of death from any cause. If a participant was not known to have died, survival was censored at the last date the participant was known to be alive. Median overall survival was estimated using the Kaplan-Meier method.

    Time frame: Baseline, Day 1 of every cycle to end-of-treatment, every 3 months during longer-term follow-up, or to death due to any cause up to 5 years

  12. Percentage of Participants Undergoing Surgical Intervention With Residual Disease Status Post-surgery

    The percentage of participants who underwent surgery during the study period with an evaluation of their disease status after surgery. The surgery during the study period was described by reason: curative, palliative, biopsy, other, or unknown. Residual disease status after surgery was described as: no residual disease due to radical surgery, presence of residual disease, unknown or not applicable.

    Time frame: At surgery, at least 6 to 8 weeks after last dose of bevacizumab up to 5 years

  13. Percentage of Participants With Best Overall Response of CR or PR by Kirsten Rat Sarcoma Viral Oncogene Homolog (K-Ras)/V-Raf Murine Sarcoma Viral Oncogene Homolog B (B-Raf) Mutation Status

    The percentage of participants with a best overall response of CR or PR according to RECIST. CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must have decreased to normal (short axis \<10 mm). No new lesions. PR was defined as ≥30% decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions. The K-Ras and/or the B-Raf gene mutation status of participants was evaluated by the central laboratory using tumor samples. Wild-type participants did not have a mutation in either gene.

    Time frame: Baseline, every 9 weeks (every 3 cycles) until end of treatment, disease progression, or withdrawal up to 5 years

  14. European Quality of Life 5 Dimension (EQ-5D) Raw-Index Score

    Quality of life (QoL) assessments were used to derive pre-specified QoL scores according to the QoL manual "EQ-5D-3 Level (3L)" user guide for instrument version 4.0. The EQ-5D is a participant rated questionnaire to assess health-related quality of life in terms of a single index value. The visual analog scale (VAS) component rates current health state on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state); higher scores indicate a better health state. The overall health score absolute changes were calculated for each participant as follows: (score at the end of treatment minus score at baseline). EQ-5D health states were converted into EQ-5D-3L raw index value by applying the scoring algorithm based on the European EQ-net VAS set. The raw index was chosen instead of rescaled index, since the questionnaire was used in order to obtain a quality of life assessment. The raw index scores ranged from 0 (worst health state) to 100 (best health state).

    Time frame: Baseline, every 9 weeks (every 3 cycles), at end-of-treatment up to 5 years

07

Results

Posted Aug 18, 2015

Participant flow

Participant flow — Overall Study
MilestoneBevacizumab+Oxaliplatin+Capecitabine/Bevacizumab
Started205
Completed0
Not completed205
Withdrew: Adverse event52
Withdrew: Progression of disease93
Withdrew: Protocol violation5
Withdrew: Participant withdrew consent13
Withdrew: Participant non-compliance5
Withdrew: Need for surgery17
Withdrew: Medical decision14
Withdrew: Death6

Outcome measures

PrimaryProgression-Free Survival (PFS): Percentage of Participants With Progressive Disease or Death

PFS was defined as the time period in months from the start of study treatment to the first observation of disease progression or death from any cause, whichever occurred first. Data for participants with no tumor assessments after baseline but who were still alive at the time of the clinical cutoff were censored at Day 1. Participants who underwent surgery after experiencing a sufficient shrinkage of the tumor, had any relapse, new occurrence of colorectal cancer, or who died were all considered as having had an event. Participants who underwent surgery without any such event were censored at the date of the last tumor assessment that documented neither a relapse nor a new colorectal cancer had occurred. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20 percent (%) increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.

Time frame:
Baseline and Day 1 of every cycle until disease progression or death up to 5 years
Reported as:
Number · percentage of participants
Progression-Free Survival (PFS): Percentage of Participants With Progressive Disease or Death
percentage of participantsBevucizamab+Oxaliplatin+Capecitabine/Bevacizumab
Progression-Free Survival (PFS): Percentage of Participants With Progressive Disease or Death50.25
SecondaryPercentage of Participants With a Best Overall Response of Complete Response (CR) or Partial Response (PR) Among Participants in the ITT Population Who Had at Least 1 Post-Baseline Assessment

The percentage of participants with a best overall response of CR or PR according to RECIST. CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must have decreased to normal (short axis less than \[\<\]10 millimeters \[mm\]). No new lesions. PR was defined as a greater than or equal to (≥) 30% decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions.

Time frame:
Baseline, every 9 weeks (every 3 cycles) until end of treatment, disease progression, or withdrawal up to 5 years
Reported as:
Number · percentage of participants
Percentage of Participants With a Best Overall Response of Complete Response (CR) or Partial Response (PR) Among Participants in the ITT Population Who Had at Least 1 Post-Baseline Assessment
percentage of participantsBevucizamab+Oxaliplatin+Capecitabine/Bevacizumab
Percentage of Participants With a Best Overall Response of Complete Response (CR) or Partial Response (PR) Among Participants in the ITT Population Who Had at Least 1 Post-Baseline Assessment58.79
SecondaryPercentage of Participants With a CR or PR Among Participants in the ITT Population

CR and PR were defined using RECIST v1.0. CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must have decreased to normal (short axis \<10 mm). No new lesions. PR was defined as a ≥30% decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions.

Time frame:
Baseline, every 9 weeks (every 3 cycles) until end of treatment, disease progression, or withdrawal up to 5 years
Reported as:
Number · percentage of participants
Percentage of Participants With a CR or PR Among Participants in the ITT Population
percentage of participantsBevucizamab+Oxaliplatin+Capecitabine/Bevacizumab
Percentage of Participants With a CR or PR Among Participants in the ITT Population49.24
PrimaryPFS: Time to Event

PFS was defined as the time period in months from the start of study treatment to the first observation of disease progression or death from any cause, whichever occurred first. Data for participants with no tumor assessments after baseline but who were still alive at the time of the clinical cutoff were censored at Day 1. Participants who underwent surgery after experiencing a sufficient shrinkage of the tumor, had any relapse, new occurrence of colorectal cancer, or who died were all considered as having had an event. Participants who underwent surgery without any such event were censored at the date of the last tumor assessment that documented that neither a relapse nor a new colorectal cancer had occurred. Median PFS was estimated using the Kaplan-Meier method.

Time frame:
Baseline and Day 1 of every cycle until disease progression or death up to 5 years
Reported as:
Median · months
PFS: Time to Event
monthsBevucizamab+Oxaliplatin+Capecitabine/Bevacizumab
PFS: Time to Event9.70 (8.43 to 10.49)
SecondaryTime to CR or PR Overall Response - Time to Event

Time to overall response (CR or PR) was calculated as the time between the date of start of treatment until first documented response (CR or PR defined per RECIST v1.0). Participants who did not achieve CR or PR were censored at the date of progression, death, or at last adequate tumor assessment date. Median time to CR or PR overall response was estimated using the Kaplan-Meier method.

Time frame:
Baseline, every 9 weeks (every 3 cycles) until end of treatment, disease progression, or withdrawal up to 5 years
Reported as:
Median · months
Time to CR or PR Overall Response - Time to Event
monthsBevucizamab+Oxaliplatin+Capecitabine/Bevacizumab
Time to CR or PR Overall Response - Time to Event3.93 (2.56 to 4.66)
SecondaryPercentage of Participants With a Best Overall Response of CR or PR During First Line Treatment

CR and PR were defined using RECIST v1.0 criteria. CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must have decreased to normal (short axis \<10 mm). No new lesions. PR was defined as a ≥30% decrease under baseline of the sum of diameters of all target lesions. Short axis was used in sum for target nodes, while longest diameter was used in sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions.

Time frame:
Baseline, every 3 weeks (every cycle) to disease progression or death up to 5 years
Reported as:
Number · percentage of participants
Percentage of Participants With a Best Overall Response of CR or PR During First Line Treatment
percentage of participantsBevucizamab+Oxaliplatin+Capecitabine/Bevacizumab
Percentage of Participants With a Best Overall Response of CR or PR During First Line Treatment54.64
SecondaryDuration of Overall Response Among Participants Whose Best Response Was CR or PR During First Line Treatment - Time to Event

For participants with a best overall response of CR or PR, the duration of overall response was measured from the time that the criteria for CR or PR (whichever occurred first) was met until the first date that progressive disease was objectively documented or until the date of death due to underlying cancer, whichever occurred first. Data for participants who did not have an event or who were alive without an objectively documented progressive disease were censored at the date of last adequate tumor assessment. Median duration of overall response was estimated using the Kaplan-Meier method.

Time frame:
Baseline, every 3 weeks (every cycle) to disease progression or death up to 5 years
Reported as:
Median · months
Duration of Overall Response Among Participants Whose Best Response Was CR or PR During First Line Treatment - Time to Event
monthsBevucizamab+Oxaliplatin+Capecitabine/Bevacizumab
Duration of Overall Response Among Participants Whose Best Response Was CR or PR During First Line Treatment - Time to Event8.52 (7.28 to 10.33)
SecondaryPercentage of Participants With a Stable Response During First Line Treatment

Stable response defined as participants with a best overall response of CR, PR, or stable disease (SD), defined using RECIST v1.0 criteria. CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must have decreased to normal (short axis \<10 mm). No new lesions. PR was defined as a ≥30% decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions. SD defined as neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease, taking as reference the smallest sum longest diameter since the treatment started.

Time frame:
Baseline, every 3 weeks (every cycle) to disease progression or death up to 5 years
Reported as:
Number · percentage of participants
Percentage of Participants With a Stable Response During First Line Treatment
percentage of participantsBevucizamab+Oxaliplatin+Capecitabine/Bevacizumab
Percentage of Participants With a Stable Response During First Line Treatment52.63
SecondaryDuration of Stable Response

For participants with a best overall response of CR, PR, or SD during first line treatment, the duration of stable response was measured from the time that the criteria for CR, PR, or SD (whichever occurred first) was met until the first date that progressive disease was objectively documented or until the date of death due to underlying cancer, whichever occurred first. Data for participants who did not have an event or who were alive without an objectively documented progressive disease were censored at the date of last adequate tumor assessment. Median duration of stable response was estimated using the Kaplan-Meier method.

Time frame:
Baseline, every 3 weeks (every cycle) to disease progression or death up to 5 years
Reported as:
Median · months
Duration of Stable Response
monthsBevucizamab+Oxaliplatin+Capecitabine/Bevacizumab
Duration of Stable Response10.39 (9.02 to 11.44)
SecondaryPercentage of Participants With Treatment Failure

Treatment-failure was defined as discontinuation of treatment for any reason, including the following qualifying events: death due to any cause, adverse event, insufficient therapeutic response (progression of disease), failure to return (lost to follow-up), refusing treatment (participant non-compliance), being unwilling to cooperate and withdrawing consent (participant withdrew consent).

Time frame:
Baseline, every 3 weeks (every cycle) to disease progression or death up to 5 years
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment Failure
percentage of participantsBevucizamab+Oxaliplatin+Capecitabine/Bevacizumab
Percentage of Participants With Treatment Failure82.74
SecondaryTime to Treatment Failure

Time to treatment-failure was defined as the time from the first day of treatment to discontinuation of treatment for any reason, including: death due to any cause, adverse event, insufficient therapeutic response (progression of disease), failure to return (lost to follow-up), refusing treatment (participant non-compliance), being unwilling to cooperate and withdrawing consent (participant withdrew consent). For participants who did not experience a qualifying event, their data were censored at the earlier of either the date of last tumour assessment or the date of the last intake of study medication. Median time to treatment-failure was estimated using the Kaplan-Meier method.

Time frame:
Baseline, every 3 weeks (every cycle) to disease progression or death up to 5 years
Reported as:
Median · months
Time to Treatment Failure
monthsBevucizamab+Oxaliplatin+Capecitabine/Bevacizumab
Time to Treatment Failure6.69 (5.97 to 7.74)
SecondaryOverall Survival: Percentage of Participants That Died Due to Any Cause

Overall survival was defined as the time from the date of the first day of treatment until the date of death from any cause. If a participant was not known to have died, survival was censored at the last date the participant was known to be alive.

Time frame:
Baseline, Day 1 of every cycle to end-of-treatment, every 3 months during longer-term follow-up, or to death due to any cause up to 5 years
Reported as:
Number · percentage of participants
Overall Survival: Percentage of Participants That Died Due to Any Cause
percentage of participantsBevucizamab+Oxaliplatin+Capecitabine/Bevacizumab
Overall Survival: Percentage of Participants That Died Due to Any Cause50.76
SecondaryOverall Survival: Time to Event

Overall survival was defined as the time from the date of the first day of treatment until the date of death from any cause. If a participant was not known to have died, survival was censored at the last date the participant was known to be alive. Median overall survival was estimated using the Kaplan-Meier method.

Time frame:
Baseline, Day 1 of every cycle to end-of-treatment, every 3 months during longer-term follow-up, or to death due to any cause up to 5 years
Reported as:
Median · months
Overall Survival: Time to Event
monthsBevucizamab+Oxaliplatin+Capecitabine/Bevacizumab
Overall Survival: Time to Event23.15 (20.07 to 27.15)
SecondaryPercentage of Participants Undergoing Surgical Intervention With Residual Disease Status Post-surgery

The percentage of participants who underwent surgery during the study period with an evaluation of their disease status after surgery. The surgery during the study period was described by reason: curative, palliative, biopsy, other, or unknown. Residual disease status after surgery was described as: no residual disease due to radical surgery, presence of residual disease, unknown or not applicable.

Time frame:
At surgery, at least 6 to 8 weeks after last dose of bevacizumab up to 5 years
Reported as:
Number · percentage of participants
Percentage of Participants Undergoing Surgical Intervention With Residual Disease Status Post-surgery
percentage of participantsBevucizamab+Oxaliplatin+Capecitabine/Bevacizumab
Curative, no residual disease55.77
Curative, residual disease13.46
Curative, unknown3.85
Curative, not applicable7.69
Palliative, no residual disease3.85
Palliative, residual disease7.69
Palliative, unknown3.85
Palliative, not applicable1.92
Biopsy, residual disease1.92
Biopsy, not applicable1.92
Unknown, unknown1.92
Unknown, not applicable3.85
Other, residual disease1.92
Other, not applicable3.85
SecondaryPercentage of Participants With Best Overall Response of CR or PR by Kirsten Rat Sarcoma Viral Oncogene Homolog (K-Ras)/V-Raf Murine Sarcoma Viral Oncogene Homolog B (B-Raf) Mutation Status

The percentage of participants with a best overall response of CR or PR according to RECIST. CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must have decreased to normal (short axis \<10 mm). No new lesions. PR was defined as ≥30% decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions. The K-Ras and/or the B-Raf gene mutation status of participants was evaluated by the central laboratory using tumor samples. Wild-type participants did not have a mutation in either gene.

Time frame:
Baseline, every 9 weeks (every 3 cycles) until end of treatment, disease progression, or withdrawal up to 5 years
Reported as:
Number · percentage of participants
Percentage of Participants With Best Overall Response of CR or PR by Kirsten Rat Sarcoma Viral Oncogene Homolog (K-Ras)/V-Raf Murine Sarcoma Viral Oncogene Homolog B (B-Raf) Mutation Status
percentage of participantsBevucizamab+Oxaliplatin+Capecitabine/Bevacizumab
Wild-type (n=18)88.89
Gene mutation (n=15)66.67
SecondaryEuropean Quality of Life 5 Dimension (EQ-5D) Raw-Index Score

Quality of life (QoL) assessments were used to derive pre-specified QoL scores according to the QoL manual "EQ-5D-3 Level (3L)" user guide for instrument version 4.0. The EQ-5D is a participant rated questionnaire to assess health-related quality of life in terms of a single index value. The visual analog scale (VAS) component rates current health state on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state); higher scores indicate a better health state. The overall health score absolute changes were calculated for each participant as follows: (score at the end of treatment minus score at baseline). EQ-5D health states were converted into EQ-5D-3L raw index value by applying the scoring algorithm based on the European EQ-net VAS set. The raw index was chosen instead of rescaled index, since the questionnaire was used in order to obtain a quality of life assessment. The raw index scores ranged from 0 (worst health state) to 100 (best health state).

Time frame:
Baseline, every 9 weeks (every 3 cycles), at end-of-treatment up to 5 years
Reported as:
Mean · units on a scale
European Quality of Life 5 Dimension (EQ-5D) Raw-Index Score
units on a scaleBevucizamab+Oxaliplatin+Capecitabine/Bevacizumab
Baseline80.24 ± 14.32
Last visit74.94 ± 19.08
Absolute change from baseline-5.30 ± 19.13
Statistical analysis
  • Bevucizamab+Oxaliplatin+Capecitabine/Bevacizumab · Signed-rank test · p = 0.0076

Adverse events

Collected over Adverse events (AE) were collected from the date of first administration of study treatment until 28 days after the last dose of study treatment up to 5 years. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Bevacizumab+Oxaliplatin+Capecitabine/Bevacizumab—56/197 (28.4%)179/197 (90.9%)
Most frequent serious events
Showing 10 of 59
Most frequent serious events
EventBevacizumab+Oxaliplatin+Capecitabine/Bevacizumab
Pulmonary embolismRespiratory, thoracic and mediastinal disorders7/197
DiarrhoeaGastrointestinal disorders4/197
SubileusGastrointestinal disorders4/197
HypersensitivityImmune system disorders3/197
PneumoniaInfections and infestations3/197
Hypertensive crisisVascular disorders3/197
Intestinal obstructionGastrointestinal disorders2/197
Intestinal perforationGastrointestinal disorders2/197
AstheniaGeneral disorders2/197
CachexiaMetabolism and nutrition disorders2/197
Most frequent other events
Showing 10 of 205
Most frequent other events
EventBevacizumab+Oxaliplatin+Capecitabine/Bevacizumab
NauseaGastrointestinal disorders84/197
DiarrhoeaGastrointestinal disorders73/197
AstheniaGeneral disorders60/197
ParaesthesiaNervous system disorders59/197
VomitingGastrointestinal disorders48/197
HypertensionVascular disorders45/197
PyrexiaGeneral disorders40/197
Neuropathy peripheralNervous system disorders38/197
NeutropeniaBlood and lymphatic system disorders32/197
Abdominal painGastrointestinal disorders29/197

Baseline characteristics

Safety population: all enrolled participants who received at least 1 dose of all study medications.

Age, Continuous
Age, Continuous(years)Bevucizamab+Oxaliplatin+Capecitabine/Bevacizumab
Mean62.25 ± 9.94
Sex: Female, Male
Sex: Female, Male(Participants)Bevucizamab+Oxaliplatin+Capecitabine/Bevacizumab
Female86
Male111
08

Study locations

38 sites
  • Bologna, 40138, Italy
  • Brescia, 25122, Italy
  • Cagliari, 09100, Italy
  • Cagliari, 09121, Italy
  • Caserta, 81100, Italy
  • Catanzaro, 88100, Italy
  • Cefalu, 90015, Italy
  • Fano, 61032, Italy
  • Firenze, 50139, Italy
  • Frattaminore, 80026, Italy
  • Grosseto, 58100, Italy
  • Ivrea, 10015, Italy
  • Latisana, 33053, Italy
  • Lecce, 73100, Italy
  • Legnago, 37045, Italy
  • Legnano, 20025, Italy
  • Macerata, 62100, Italy
  • Napoli, 80131, Italy
  • Negrar, 37024, Italy
  • Orbassano, 10043, Italy
  • Padova, 35128, Italy
  • Palermo, 90127, Italy
  • Palermo, 90146, Italy
  • Pavia, 27100, Italy
  • Reggio Calabria, 89100, Italy
  • Reggio Emilia, 42100, Italy
  • Rionero in Vulture, 85028, Italy
  • Roma, 00152, Italy
  • Roma, 00184, Italy
  • Roma, 00186, Italy
  • Roma, 00189, Italy
  • Salerno, 84131, Italy
  • San Giovanni Rotondo, 71013, Italy
  • Sondrio, 23100, Italy
  • Taormina, 98030, Italy
  • Torino, 10125, Italy
  • Torino, 10153, Italy
  • Verbania, 28921, Italy
09

References and documents

Publications

  • Antonuzzo L, Giommoni E, Pastorelli D, Latiano T, Pavese I, Azzarello D, Aieta M, Pastina I, Di Fabio F, Bertolini A, Corsi DC, Mogavero S, Angelini V, Pazzagli M, Di Costanzo F. Bevacizumab plus XELOX as first-line treatment of metastatic colorectal cancer: The OBELIX study. World J Gastroenterol. 2015 Jun 21;21(23):7281-8. doi: 10.3748/wjg.v21.i23.7281. PubMed 26109816 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2008, a primary completion of Aug 2011 and a completion of Aug 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2015, 4 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 18, 2007
First posted
Dec 19, 2007
Start
Feb 2008
Primary completionActual
Aug 2011
CompletionActual
Aug 2011
Results first posted
Aug 18, 2015
Last update
Aug 18, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 18, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00577031
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Dec 19, 2007
Start date
Feb 2008
Primary completion
Aug 2011
Completion
Aug 2011
Results posted
Aug 18, 2015
Last update
Aug 18, 2015

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Bevacizumab · Oxaliplatin · Capecitabine

Start the discussion